Table 3.

Patient data for in vivo validation procedures

Patient no.	Primary tumor phenotype	Metastasis phenotype	Number of CTCs*	CTC phenotype §
1	ER+/HER2−	ER−/HER2−	48	ER−/HER2+
2	ER+/HER2−	n/a	35	ER−/HER2−
3	ER+/HER2−	ER+/HER2−	3	n/a‡
4	n/a	ER+/HER2−	12	ER+/HER2−
5	ER−/HER2+	n/a	111	ER−/HER2−
6	ER−/HER2+	n/a	311	ER−/HER2−
7	ER+/HER2−	ER+/HER2−	107	ER+/HER2−
8	ER+/HER2−	ER+/HER2−	0	Negative control
9	ER+/HER2−	ER+/HER2−	0	Negative control

*As defined by CellSearch, single samples assessed 0–6 months from initiation of therapy against metastatic disease.

^§Phenotype according to CTC-DropMount. Criteria for biomarker positivity were ≥1 ER⁺ CTC, and ≥1 HER2⁺ CTC.

^‡In this patient no CTCs were identified following secondary staining.

Patients 8, and 9 were selected as negative controls. Neither of these patients had detectable CTCs following secondary staining.